Get the Stockscreener App
30.95
0.78%
0.24
After Hours:
30.95
Collegium Pharmaceutical Inc stock is traded at $30.95, with a volume of 350.63K.
It is up +0.78% in the last 24 hours and up +8.14% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$30.71
Open:
$30.86
24h Volume:
350.63K
Relative Volume:
0.82
Market Cap:
$998.14M
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
26.01
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
-4.80%
1M Performance:
+8.14%
6M Performance:
-9.37%
1Y Performance:
-6.89%
1-Day Range:
$30.58
$31.52
1-Week Range:
$30.23
$32.87
52-Week Range:
$28.39
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
30.95 | 998.14M | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price - Defense World
Collegium Pharmaceutical expands board, appoints new director - MSN
Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors -February 05, 2025 at 08:00 am EST - Marketscreener.com
Collegium Pharmaceutical expands board, appoints new director By Investing.com - Investing.com South Africa
Collegium Pharmaceutical expands board with new director - Investing.com India
Collegium Pharmaceutical Expands Board with Nancy Lurker - TipRanks
Collegium Appoints Nancy S. Lurker to its Board of Directors - GlobeNewswire
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Collegium Pharmaceutical Insiders Sell US$2.3m Of Stock, Possibly Signalling Caution - Simply Wall St
Piper Sandler Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $36.00 - MarketBeat
SG Americas Securities LLC Sells 4,586 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $100 million worth of its shares. - Marketscreener.com
Pacer Advisors Inc. Trims Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Nisa Investment Advisors LLC Has $71,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check - FiercePharma
Assenagon Asset Management S.A. Trims Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Assenagon Asset Management S.A. Has $4.31 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Ritholtz Wealth Management Has $968,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Needham Upgrades Collegium Pharmaceutical (COLL) - MSN
Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80 - Defense World
Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock By Investing.com - Investing.com Australia
Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 27,500 Shares of Stock - MarketBeat
Despite the downward trend in earnings at Collegium Pharmaceutical (NASDAQ:COLL) the stock swells 18%, bringing three-year gains to 82% - Simply Wall St
Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock - Investing.com
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has $10.71 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
JPMorgan Chase & Co. Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) Raised to “Buy” at Needham & Company LLC - Defense World
Collegium Pharma spikes after 2025 outlook - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLC - MarketBeat
Collegium Pharmaceutical Unveils 2025 Financial Projections - Yahoo Finance
COLLCollegium Pharmaceutical, Inc. Latest Stock News & Market Updates - StockTitan
Collegium Pharmaceutical (NASDAQ:COLL) Trading 2.8% HigherShould You Buy? - MarketBeat
Collegium Pharma stock spikes on 2025 outlook (COLL:NASDAQ) - Seeking Alpha
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2025 -January 08, 2025 at 08:00 am EST - Marketscreener.com
Collegium Provides 2025 Financial Guidance and Business Update - GlobeNewswire
Collegium Pharmaceutical Projects Record $750M Revenue in 2025, ADHD Drug Leads Growth - StockTitan
Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month LowHere's What Happened - MarketBeat
Collegium stock hits 52-week low at $28.46 amid market challenges - Investing.com Australia
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month LowWhat's Next? - MarketBeat
Franklin Resources Inc. Has $1.16 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Geode Capital Management LLC Has $29.97 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus - Yahoo Finance
Sanctuary Advisors LLC Buys 1,731 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Barclays PLC - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Barclays PLC - Defense World
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):